What changed in Corcept Therapeutics Inc's latest annual report
In the year ended 31 Dec 2025, Corcept Therapeutics Inc's revenue rose 12.8% to USD 761.41m, from USD 675.04m; net income fell 29.4% to USD 99.65m, from USD 141.21m; total liabilities rose 17.3% to USD 188.85m, from USD 160.96m.
Year ended 31 Dec 2025. Source: 10-K filed 24 Feb 2026, read it on SEC EDGAR.
USD 675.04m to USD 761.41m
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 675.04m | 761.41m | Up 12.8% |
| Net income | 141.21m | 99.65m | Down 29.4% |
| Total assets | 840.55m | 836.65m | Down 0.5% |
| Total liabilities | 160.96m | 188.85m | Up 17.3% |
| Cash and cash equivalents | 127.67m | 120.50m | Down 5.6% |
| Shareholders' equity | 679.59m | 647.80m | Down 4.7% |
Questions people ask
Did Corcept Therapeutics Inc's revenue grow last year?
Revenue grew 12.8%, from USD 675.04m to USD 761.41m in the year ended 31 Dec 2025.
Is Corcept Therapeutics Inc profitable?
Yes. Net income was USD 99.65m in the year ended 31 Dec 2025. The year before: USD 141.21m.
How much cash and debt does Corcept Therapeutics Inc have?
At its latest year end (31 Dec 2025), Corcept Therapeutics Inc reported cash and cash equivalents of USD 120.50m.
Where do these numbers come from?
From Corcept Therapeutics Inc's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Corcept Therapeutics Inc?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%